8-K: Avant Technologies Forms Biotech Joint Venture Klothonova

Avant Technologies Inc. has entered a joint venture with SGAustria Pte. Ltd. to form Klothonova Inc., focusing on cell-based treatments for age-related diseases.

Summary

• Avant Technologies Inc. (AVAI) and SGAustria Pte. Ltd. (Austrianova) have formed a new Nevada corporation, Klothonova Inc., through a Joint Venture and License Agreement.
• Klothonova's purpose is to develop, use, and commercialize treatments for Alzheimer's disease, heart disease, cancer, kidney disease, and other age-related conditions, as well as for promoting longevity, using encapsulated Klotho-producing cells.
• Austrianova contributes its proprietary cell encapsulation technology, intellectual property, know-how, and resources, including expertise in cell biology and GMP-grade cell products.
• AVAI will provide all resources and capital for Klothonova's formation and operation for the next 18 months, not to exceed $1.5 million USD.
• AVAI will also use its best efforts to arrange additional funding as needed, at no cost to Austrianova.
• Ownership of Klothonova will be 50% AVAI and 50% Austrianova, with each holding 1,500,000 shares of common stock.
• Klothonova will be governed by a Board of Directors with one representative from each party, and an independent third-party mediator for deadlock resolution.
• Kenn Kerr will serve as Klothonova's Chief Executive Officer, and Walter H. Gnzburg, Ph.D., will be the Chairman of the Board.
• The agreement has an initial term of five years, automatically renewed annually.

Sentiment

Score: 8

Explanation: The formation of a new biotech joint venture with significant initial funding and a clear strategic focus on high-potential therapeutic areas (age-related diseases, longevity) using proprietary technology is a strong positive development for Avant Technologies Inc. The substantial financial commitment and shared ownership indicate confidence in the venture's prospects, despite inherent risks in biotech development.

Positives

• Establishes a new joint venture, Klothonova Inc., with a clear focus on high-potential biotech treatments for major age-related diseases.
• Secures an exclusive license to Austrianova's proprietary cell encapsulation technology, backed by over 50 international peer-reviewed publications and industry contracts.
• AVAI commits significant initial funding of up to $1.5 million USD for Klothonova's first 18 months of operation, ensuring a strong start.
• The potential for an additional $8.5 million USD loan from AVAI provides a clear pathway for further development and clinical testing.
• The 50/50 ownership structure allows AVAI to share equally in the potential upside of Klothonova's future successes.
• The appointment of experienced leadership (Kenn Kerr as CEO, Walter H. Gnzburg as Chairman) for Klothonova provides strong operational and strategic guidance.

Negatives

• AVAI is committing up to $1.5 million USD in capital for the initial 18 months, representing a significant financial outlay.
• AVAI has agreed to provide an additional $8.5 million USD follow-up financing in the form of a loan, increasing its financial exposure to the joint venture.
• If AVAI decides not to provide the $8.5 million follow-up financing, Austrianova is free to proceed with further development of the encapsulated cell product outside of Klothonova, and Klothonova will have no rights to these developments, potentially limiting future growth.
• The collateral for the $8.5 million loan is limited to Klothonova's cash flow, excluding Austrianova's background IP, new IP, or Klothonova's new IP, which could impact recovery in case of default.

Risks

• Actual results may differ materially from forward-looking statements concerning future financing arrangements and business strategy due to inherent risks and uncertainties.
• Failure by either party to fulfill its obligations under the agreement could lead to dilution of the breaching party's ownership interest in Klothonova.
• Regulatory approvals may be required for conducting the business, and there is no representation regarding such approvals.
• Deadlock in decision-making at the Board level could require intervention by an independent third-party mediator, potentially slowing progress.
• The agreement can be terminated due to lack of funding, material breach, dissolution/bankruptcy of a party, change of control, or Force Majeure events.
• Upon termination, all IP licensed from Austrianova to Klothonova will revert to Austrianova, and Klothonova will lose rights to the technology.
• No party will be liable for indirect, incidental, or consequential damages (including lost profits) for a breach of the agreement.

Future Outlook

The company anticipates future financing arrangements and aims to develop, use, and commercialize treatments for various medical conditions, including Alzheimer's disease, heart disease, cancer, kidney disease, and other age-related conditions, as well as for promoting longevity, based on the overexpression of the Klotho protein. These forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.

Management Comments

• Vitalis Racius, Chief Financial Officer, Director & Treasurer of Avant Technologies Inc., signed the 8-K report.
• Kenn Kerr will serve as the Chief Executive Officer of Klothonova Inc.
• Walter H. Gnzburg, Ph.D., will initially serve as Chairman of the Board for Klothonova Inc.
• Chris Winter, CEO of Avant Technologies Inc., signed the Joint Venture & License Agreement.
• Brian Salmons, CEO of SGAustria Pte Ltd, signed the Joint Venture & License Agreement.

Industry Context

This joint venture positions Avant Technologies Inc. to enter the rapidly growing and high-value biotech sector, specifically targeting age-related diseases and longevity. The use of proprietary cell encapsulation technology aligns with advanced therapeutic trends, offering a novel approach to delivering therapeutic proteins. This move could diversify AVAI's portfolio and tap into a market with significant unmet medical needs and substantial commercial potential, competing with other biotech firms developing cell-based therapies and regenerative medicine.

Comparison to Industry Standards

• The 50/50 joint venture structure is common in early-stage biotech collaborations, allowing for shared risk and reward between a technology provider (Austrianova) and a funding/commercialization partner (AVAI).
• The initial funding commitment of $1.5 million for 18 months, followed by a potential $8.5 million loan, is a substantial investment for a new biotech entity, indicating strong belief in the underlying technology and market opportunity.
• Austrianova's expertise in GMP-grade cell products and over 50 peer-reviewed publications suggests a robust scientific foundation, comparable to reputable academic spin-offs or specialized biotech firms.
• The focus on Klotho protein for age-related conditions like Alzheimer's, heart disease, and cancer places Klothonova in a highly competitive but potentially lucrative therapeutic area, similar to companies pursuing gene therapies or advanced biologics for chronic diseases.

Management Changes

Corporate Governance

Related Party Transactions

• Avant Technologies Inc. (AVAI) and SGAustria Pte. Ltd. (Austrianova) are entering into a Joint Venture and License Agreement to form Klothonova Inc., with each party holding 50% ownership.
• AVAI will provide initial capital of up to $1.5 million USD and potentially an additional $8.5 million USD loan to Klothonova.
• Austrianova will provide an exclusive license for its cell encapsulation technology to Klothonova and will provide services for research, development, manufacturing, and supply of the Klotho Product, which will be invoiced to Klothonova.

Stakeholder Impact

• Shareholders (AVAI): Potential for significant long-term value creation through entry into the high-growth biotech sector targeting major diseases, balanced by initial capital commitment and potential loan exposure.
• Employees (Klothonova): Creation of new employment opportunities within the biotech research and development field.
• Customers/Patients: Potential for new therapeutic treatments for Alzheimer's, heart disease, cancer, kidney disease, and other age-related conditions.
• Austrianova: Gains a commercialization partner and significant funding for its proprietary technology, expanding its market reach and development capabilities.
• Creditors (AVAI): The $8.5 million loan to Klothonova will be collateralized only by Klothonova's cash flow, not its intellectual property, which may affect recovery in certain scenarios.

Next Steps

• Formal establishment of Klothonova Inc. as a Nevada Corporation.
• Preparation and approval of an Annual Plan detailing Klothonova's goals and procedures.
• Further development of the encapsulated cell product for the stated purpose, including clinical trials.
• Regulatory work and product registration in various jurisdictions.
• Potential arrangement of additional funding from strategic investors beyond the initial $10 million USD from AVAI.

Key Dates

Recommendation

The formation of Klothonova Inc. represents a highly strategic and potentially transformative move for Avant Technologies Inc. The joint venture with Austrianova, a reputable biotech firm, provides AVAI with a 50% stake in a company focused on cutting-edge cell-based treatments for major age-related diseases and longevity. AVAI's substantial financial commitment of up to $1.5 million in equity and a potential $8.5 million loan demonstrates strong confidence in the venture's prospects. This entry into the high-growth biotech sector, leveraging proprietary technology, offers significant long-term value creation potential for shareholders. The defined governance and funding structure mitigate initial risks, making this a compelling investment opportunity.

Keywords

Joint Venture, Biotech, Cell Encapsulation, Klotho Protein, Alzheimer's Disease, Heart Disease, Cancer, Kidney Disease, Longevity, Age-Related Conditions, SEC Filing, AVAI, Austrianova, Klothonova